Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Intarcia Therapeutics Clear all
Completed Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

NCT01455870
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 60 mcg/day, sitagliptin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Long Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 1, 2026, 10:34 PM EDT
Terminated Phase 3 Interventional

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

NCT01785771
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 (exenatide in DUROS)
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
51
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Chandler, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 1, 2026, 10:34 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

NCT01455909
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 60 mcg/day, sitagliptin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 1, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

NCT02641899
View directory record Official record
Conditions
Healthy
Interventions
ITCA 650 20/60 mcg/day, Acetaminophen, Atorvastatin, Lisinopril, Warfarin, Digoxin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 1, 2026, 10:34 PM EDT
Completed Phase 3 Interventional

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

NCT02638805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
ITCA 650 Osmotic Mini Pump 20/60 mcg/day, ITCA 650 Osmotic Mini Pump 60 mcg/day, Metformin, Liraglutide
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 1, 2026, 10:34 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

NCT01455896
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650, ITCA placebo
Drug · Other
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
4,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
34
States / cities
Chandler, Arizona • Hayward, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 1, 2026, 10:34 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

NCT01455883
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 60 mcg/day, glimepiride
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 1, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

NCT02641990
View directory record Official record
Conditions
Healthy Adult Premenopausal Female Volunteers
Interventions
ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 1, 2026, 10:34 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

NCT01455922
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650, glimepiride
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 1, 2026, 10:34 PM EDT
Terminated Phase 3 Interventional

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

NCT00097344
View directory record Official record
Conditions
Breast Neoplasms, Neoplasms, Hormone-Dependent
Interventions
Atamestane, Toremifene, Letrozole, Aromatase inhibition, Estrogen receptor blocker, Hormone therapy, Endocrine therapy, Antiestrogen therapy
Drug · Procedure
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
49
States / cities
Mobile, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Oct 1, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

NCT00943917
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650, Exenatide Injection, Ex Inj/ITCA 650
Other · Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
50
States / cities
Chino, California • La Jolla, California • National City, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 1, 2026, 10:34 PM EDT
Terminated Phase 3 Interventional

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00010322
View directory record Official record
Conditions
Breast Cancer
Interventions
atamestane, toremifene
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Purchase, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 1, 2026, 10:34 PM EDT
Terminated Phase 3 Interventional

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

NCT00267553
View directory record Official record
Conditions
Breast Neoplasms, Neoplasms, Hormone-Dependent
Interventions
Atamestane, toremifene, letrozole
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Greenbrae, California • Saint Joseph, Michigan • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2007 · Synced Oct 1, 2026, 10:34 PM EDT
Terminated Phase 3 Interventional

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

NCT03060980
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
ITCA 650 20/60 mcg/day, Empagliflozin (oral), Glimepiride (oral)
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
96
States / cities
Fountain Hills, Arizona • Glendale, Arizona • Phoenix, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 1, 2026, 10:34 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

NCT01455857
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650, ITCA placebo
Drug · Other
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
121
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 1, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Results available

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

NCT01798264
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 (exenatide in DUROS)
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
30 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Miami Gardens, Florida • Cincinnati, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 1, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment

NCT00519792
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Omega DUROS device
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 1, 2026, 10:34 PM EDT
Completed Phase 3 Interventional

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

NCT00044291
View directory record Official record
Conditions
Breast Neoplasms, Neoplasms, Hormone-dependent
Interventions
atamestane, toremifene, letrozole, aromatase inhibition, hormone therapy, endocrine therapy, antiestrogen therapy
Drug · Procedure
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
17
States / cities
Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 1, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

NCT02320045
View directory record Official record
Conditions
Renal Insufficiency
Interventions
ITCA 650 (Exenatide in osmotic mini pump)
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
25 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 1, 2026, 10:34 PM EDT